Jonathan Hurov, PhD
Vice President, Discovery Biology & Platforms, Cygnal Therapeutics
Jonathan Hurov joined Cygnal Therapeutics as its third employee in September 2016. Prior to Cygnal, he served multiple roles as Director at Agios Pharmaceuticals over a period of 7 years, including project leader, discovery team lead, and translational biology lead. His first industry position was senior scientist in the Wyeth Pharmaceuticals Metabolic Disease group.
Jonathan completed his postdoctoral training in the laboratory of Dr. Lewis Cantley at Harvard Medical School, studying the role of lipid and protein kinases in the regulation of metabolism. He received his undergraduate degree in Biochemistry at the University of Victoria in British Columbia, Canada and completed his Ph.D. training as a Markey Pathway student at Washington University in St. Louis.